Connect with us on:       

November 13, 2012
Issue 131

In This Newsletter

Get your Holiday Message to your audience, effectively.  HealthEconomics.Com can help.  Contact Michele Musci at

New Jobs posted! Looking for employment or recruiting? Check out our NEW Resume database to upload CVs.

In this issue:

Need better exposure for your company? Use the HealthEconomics.Com Partnership program to reach 20,500 HEOR professionals around the world. Options for every budget. Contact us.

Industry News

Who Was A Top Influencer at ISPOR Berlin? HealthEconomics.Com. HealthEconomics.Com (@www_healthecon) was a Top Influencer of ISPOR Berlin, based on Symplur’s Social Media Hashtag analysis of tweets. Other top influencers were Mervyn Hall (@CuroMerv) and Carrot Pharma (@carrotpharma). At your next meeting, consider the value of this, and let HealthEconomics.Com tweet for you to our almost 2,000 followers, the most of ANY organization in the health economics/market access field.

Pharma Really IS Sounding Like Late-Night Infomercials: Sanofi runs Half-Off Sale on Zaltrap! Sanofi's Zaltrap has seen market resistance in the U.S., so the French drugmaker is cutting the price in order to raise awareness and use of the product. Will this have a ripple effect on other expensive treatments and on VBP? (Source: FiercePharma, 11/8/2012)

Podcast (Listen Anytime): Health Policy Implications from a 2nd Obama Administration. Peyton Howell, President of AmerisourceBergen Consulting Services, outlines health policy implications from a 2nd Obama administration, with focus on the ACA implementation.

Sanofi’s Todd S. Michael Presents on Value and Real-World Evidence in CER. You can download this presentation by Michael from a recent Health Network Communications event in the lead up to their Evidence 2013 event in February.

HealthCare Economics: Interview with Economist Jonathan Gruber.
Jonathan Gruber. American economist & MIT Professor, involved in healthcare reform in Massachusetts with Gov. Mitt Romney. Read his interesting views here. (Source: The Politic, 11/3/2012)
White Paper: Pricing Teams Weighing In Earlier. See what’s happening industry-wide.  However, HealthEconomics.Com wonders about impact of these price-slashing agreements, and how it undermines the pricing models and VBP? (Source: Cutting Edge Information, 11/2012)
US Pharma Trends, Post-Election: Rita Numerof predicts the following for Pharma:  downward reimbursement, more consolidation of companies, greater personalized medicine and diagnostic patient targeting, more robust evidence requirements, and growth in med device/diagnostic sectors.  PPACA will dampen appetite for innovation. (Source: Fierce Pharma, Nov. 8, 2012)

Merck Invests Big in Informatics for Personalized Medicine.
Merck is partnering with the Regenstrief Institute, an informatics and research organization, on a five-year agreement to use data analytics to develop personalized medicine treatments. (Source:, 11/9/2012)

Is Big Pharma Utilizing Too Many Resources on Potential Blockbusters?
Pharmas investment to bring a drug to market can be ginormous and there is no guarantee of success. Is it wiser for pharma to invest in major therapeutic areas (i.e. Cardiovascular, diabetes etc) or to focus on smaller unmet needs? Forbes contributor John LaMattina presents the case here. (Source: Forbes, 11/7/2012)

Call for Speakers: Pricing & Profit Optimization forum - High Tech. The European Pricing Platform is seeking you to share expertise and best practices for this February 2013 event in Cologne.
NICE seeks new members for its Diagnostics Advisory Committee. This Committee considers and interprets evidence on the clinical and cost effectiveness of diagnostic technologies as defined in the relevant EU directives, and formulates recommendations to the Institute on their use in the National Health Service. Do you have the skills and experience they are looking for?

Cancer Costs the UK £15.8 Billion per Year. The study was led by Dr Jose Leal from the Health Economics Research Centre at the University of Oxford. (Source: OnlyMedics, 11/8/2012)

New European Action Plan for Ageing Population. The European Commission plans to address six key health issues related to an increasingly elderly population. Included are: presciption adherence, improved care for chronic disease, fall prevention, diet and exercise and independent living. Tele-monitoring as well as information and communcation technology systems which enable social contact are also to be addressed. (Source: PMLiVE, 11/8/2012)

Who is EUnetHTA?  Whoa, This is a BIG Mission! Formed in 2008, European Network for Health Technology Assessment  is implementing the proposal for a sustainable, permanent collaboration for HTA in Europe, attempting to unite government organisations from EU Member States, EEA and EFTA countries and a large number of relevant regional agencies and NPOs involved in HTA.

How Will PCORI Survive Looming Funding Cuts? Under the ACA, funding for PCORI will cease as of July 1, 2019. To survive, PCORI must demonstrate value, by focusing on high-impact problems that can be solved the shortest possible time. Are they up to the task? (Source: Huff Post Health News, 10/29/2013)
India: Pharma companies fail to fall in line on prices. Pharma companies in India continue to overprice their drugs despite the National Pharmaceutical Pricing Authority (NPPA) imposing fines several times in the last 17 years. The actual figures of drug overpricing are not known. The prices of scheduled bulk drugs and formulations are controlled by NPPA under the Drugs (Price Control) Order (DPCO), 1995. The MRP of a scheduled drug formulation is fixed after adding statutory duties such as excise duty and valueadded tax to the price determined under the order. (Source: BusinessToday, 10/26/2012)

... Read All News
Spotlight 1 of the Week

Spotlight 2 of the Week

Survey of the Week

Please participate in PharmaNet/i3’s celebrated 
7th Survey on Observational Research:

for a chance to win iPAD. 15 minutes. 

Important insights, findings available.


10-things NOT to do when choosing a patient experience measure. Keith Meadows of the patientoutcomesblog shares a list of 'Do Nots' when choosing a PREM. Read his list here. Have more to add? (Source: thepatientoutcomesblog, 11/8/2012)

Peruse the Educational Resources on HealthEconomics.Com by clicking here.

Job of the Week

Senior Health Economics and Outcomes Researcher

Bowie, MD – HEOR, Real Pharma

Reserve "Job of the Week". Contact us.

Link of the Week

Research | Value Messaging | Access | Adherence

eMAX Health, a research leader in demonstrating evidence of value and improving access for pharmaceuticals

Reserve "Link of the Week". Contact Us.

Conference Of The Week

Learn to adapt to the changing healthcare landscape by cultivating successful relationships and increase market share with ACOs.

Partnering with ACOs Boot Camp, Dec. 4-5, Philadelphia

Reserve "Conference of the Week". Contact us.

Job Title Location
Senior Health Economics and Outcomes Researcher - Bowie, MD - HEOR
Real Staffing Group
Bowie, Maryland
Senior Actuarial Analyst - Eden Prairie, MN
United Health Group
Eden Prairie, Minnesota
Senior Business Intelligence Analyst - Pittsburgh, PA
United Health Group
Pittsburgh, Pennsylvania
SAS Healthcare Economics Analyst - Phoenix, AZ or Santa Ana, CA
United Health Group
Phoenix, Arizona
Psychometrician with measurement focus
Adelphi Values
Boston, Massachusetts
View All Jobs

Dates Webinar Title
Oct 23 - Nov 23, 2012 Time and Motion Studies
View All Webinars